Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $10.00 Average PT from Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned an average rating of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $10.00.

VTYX has been the subject of a number of analyst reports. Canaccord Genuity Group reduced their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 12th. Wells Fargo & Company dropped their price target on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Oppenheimer reissued an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th.

Institutional Investors Weigh In On Ventyx Biosciences

A number of large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new position in shares of Ventyx Biosciences during the 2nd quarter valued at about $608,000. Deerfield Management Company L.P. Series C raised its position in Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after purchasing an additional 2,287,570 shares during the period. Cubist Systematic Strategies LLC grew its holdings in shares of Ventyx Biosciences by 165.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company’s stock worth $345,000 after purchasing an additional 93,247 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the period. Finally, Squarepoint Ops LLC boosted its stake in Ventyx Biosciences by 101.3% during the second quarter. Squarepoint Ops LLC now owns 76,539 shares of the company’s stock worth $177,000 after buying an additional 38,524 shares during the period. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Ventyx Biosciences Stock Performance

VTYX stock opened at $1.85 on Friday. Ventyx Biosciences has a one year low of $1.67 and a one year high of $11.48. The firm’s fifty day moving average is $2.19 and its 200 day moving average is $2.66. The firm has a market cap of $130.82 million, a PE ratio of -0.78 and a beta of 0.37.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.